Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Must Reads In Breast Cancer
Breast Cancer for November/December 2015
FDA Approves Vistogard, Indicated as chemotherapy antidote
Lymphedema in Breast Cancer, Assessing the effects of blood draws, injections, and travel
Unconjugated Estradiol Levels in Breast Cancer, Studying associations with body mass index
FDA Approves Hair-Conserving Device, DigniCap may help patients with breast cancer during chemo
ACS/ASCO Joint Guideline on BC Survivor Care, An evidence-based guideline derived from literature review
Breast Cancer for September/October 2015
Screening Mammographies in Premenopausal Women, Comparing annual vs biennial screening
STILs as Prognosticators of Recurrence-Free Survival, Does trastuzumab affect predictions?
Patients With Heavily Pre-treated Breast Cancer, Comparing etirinotecan pegol to treatment of physician's choice
Fine Scale Mapping of the 4q24 Locus, Does it reveal breast cancer risk?
Menses Recovery After BC Therapy, Does GnRHa affect future pregnancy?
Breast Cancer for July/August 2015
A Revised Prognostic Model for BC, A risk assessment tool incorporating breast density
Weight Loss Intervention in BC Survivors, Can it have clinically meaningful effects?
Multigene Panel Testing in BC, OC, Assessing risks beyond BRCA1/2 mutations
Hormone Receptor Status in BC, Associating HR status with BRCA1/2 mutations
Hypofractionated Radiation Therapy in BC, How does it compare to conventional fractionation?